Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Neurology

Topics

Medicine

Immunology

Pathology

Internal Medicine

Pediatrics

Show all topics

DOI

10.1016/s1474-4422(17)30378-2

Other Formats

PDF